Subsidy Information and Financing Scheme MAFTepotinib Tablet 225 mg Treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition f... See all × MAFTepotinib Tablet 225 mg Treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor gene exon 14 skipping (METex14sk) alterations. MSHLTepotinib Tablet 225 mg Treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition f... See all × MSHLTepotinib Tablet 225 mg Treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor gene exon 14 skipping (METex14sk) alterations.
Drug Guidance for Subsidy 31/08/2022 Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer The Ministry of Health’s Drug Advisory Committee has recommended: Tepotinib 225 mg tablet fo... See all × 31/08/2022 Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer The Ministry of Health’s Drug Advisory Committee has recommended: Tepotinib 225 mg tablet for treating metastatic mesenchymal epithelial transition exon 14 skipping (METex14sk) mutation-positive non-small-cell lung cancer (NSCLC) in line with specific clinical criteria. Funding status RTepotinib 225 mg tablet is recommended for inclusion on the MOH Cancer Drug List (CDL; MAF with MediShield Life monthly claim limit of $1,600) for the abovementioned indication from 1 September 2022. NRCDL listing does not apply to any formulations or strengths of capmatinib for treating metastatic METex14sk mutation-positive NSCLC. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 225 mg National Cancer Centre Tan Tock Seng Hospital